BD unveils second-gen Nano pen needle
BD is launching a new iteration of its BD Nano pen needles. The company recently received the Food and Drug Administration’s blessing for the BD Nano second-generation pen needles, which it said is meant to offer people who inject diabetes medications a more reliable subcutaneous delivery of their medication to manage their condition.
The BD Nano second-generation pen needles use a contoured needle base to help mitigate the risks resulting from user injection force variability, and it concentrates, then distributes pressure closely around the injection site to compensate for variable injection forces. Doing so, the company said, allows for a more reliable target depth than other 4-mm pen needles.
The new design has demonstrated more reliable subcutaneous injection depth resulting in up to an eight-fold reduction in calculated intramuscular injection risk, according to BD. It also features a new ergonomic design meant to make it easier to use.
"The launch of BD Nano second-generation pen needles reinforces BD's commitment to providing the most advanced solutions possible for people with diabetes to help achieve better clinical management of insulin use," Stanislav Glezer, BD’s global vice president of medical affairs, said.
The new launch includes all the benefits its predecessor pen needle has, including BD's 32G x 4 mm pen needle with five-bevel PentaPoint comfort, which has been clinically shown to enter the skin more easily than other three-bevel needles, as well as its extra thin wall EasyFlow technology that increases the medication flow rate, BD said.
BD Nano second-generation pen needles are expected to be commercially available in mid-2019.
The BD Nano second-generation pen needles use a contoured needle base to help mitigate the risks resulting from user injection force variability, and it concentrates, then distributes pressure closely around the injection site to compensate for variable injection forces. Doing so, the company said, allows for a more reliable target depth than other 4-mm pen needles.
The new design has demonstrated more reliable subcutaneous injection depth resulting in up to an eight-fold reduction in calculated intramuscular injection risk, according to BD. It also features a new ergonomic design meant to make it easier to use.
"The launch of BD Nano second-generation pen needles reinforces BD's commitment to providing the most advanced solutions possible for people with diabetes to help achieve better clinical management of insulin use," Stanislav Glezer, BD’s global vice president of medical affairs, said.
The new launch includes all the benefits its predecessor pen needle has, including BD's 32G x 4 mm pen needle with five-bevel PentaPoint comfort, which has been clinically shown to enter the skin more easily than other three-bevel needles, as well as its extra thin wall EasyFlow technology that increases the medication flow rate, BD said.
BD Nano second-generation pen needles are expected to be commercially available in mid-2019.